We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Study confirms vaccine being used in global efforts to achieve and sustain polio eradication is successfully interrupting polio outbreaks whilst minimising risk of new vaccine-derived outbreaks in Uganda
Paracetamol should be taken as directed in the patient information leaflet.
The Medicines and Healthcare products Regulatory Agency (MHRA) approved a maximum dose of up to 7.2mg per week of semaglutide (Wegovy) on 6 January 2026.
The MHRA is now setting out the next phase of reforms for 2026, aimed at helping patients access new cutting-edge treatments more quickly and boosting the UK’s competitiveness for global clinical research.
Updated product information and packaging will help patients better understand the risks of dependency, addiction, and withdrawal with these medicines.
As medicines and medical technologies become more complex, there are exciting opportunities to further strengthen our safety monitoring systems.
As with any medicine, the MHRA will keep the safety and effectiveness of Nirogacestat hydrobromide under close review.
In this new role, Professor George will lead the Agency’s science strategy and will oversee the MHRA’s scientific, research and innovation activities.
As with any medicine, the MHRA will keep the safety and effectiveness of zapomeran under close review.
As many people consider lifestyle changes at the start of the year, the Medicines and Healthcare products Regulatory Agency (MHRA) is urging the public to make sure any weight-loss medicines they use are safe, effective and …
As colder weather arrives, the Medicines and Healthcare products Regulatory Agency (MHRA) and the National Fire Chiefs Council (NFCC) are urging the public to be aware of fire risks linked to emollient skin creams.
Understanding gut microbiome interactions with medicines could help explain differences in how people respond to treatment and build on existing medicine safety knowledge to support safer, more effective prescribing in the f…
As the cold weather sets in and coughs and colds become more common, the MHRA is reminding people that small, everyday choices can make a big difference to winter wellbeing.
As with any medicine, the MHRA will keep the safety and effectiveness of lenacapavir under close review.
National Commission is seeking evidence to shape regulation of AI in healthcare and support the UK’s ambition for a world-leading, AI-enabled NHS
Updated MHRA guidance will help health institutions, such as NHS Trusts and Boards, safely design and make general medical devices for patients.
Exploring the MHRA's transformational impact on access, experience, and outcomes.
As with any medicine, the MHRA will keep the safety and effectiveness of depemokimab under close review.
As with any medicine, the MHRA will keep the safety and effectiveness of fluticasone propionate under close review.
This holiday season, the MHRA is reminding people that some common festive foods can interact with medicines, altering how well they work or increasing the risk of side effects.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab and requires JavaScript).